» Articles » PMID: 35836354

Distinguishing Post-translational Modifications in Dominantly Inherited Frontotemporal Dementias: FTLD-TDP Type A (GRN) Vs Type B (C9orf72)

Overview
Specialty Neurology
Date 2022 Jul 15
PMID 35836354
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Frontotemporal dementias are neuropathologically characterised by frontotemporal lobar degeneration (FTLD). Intraneuronal inclusions of transactive response DNA-binding protein 43 kDa (TDP-43) are the defining pathological hallmark of approximately half of the FTLD cases, being referred to as FTLD-TDP. The classification of FTLD-TDP into five subtypes (Type A to Type E) is based on pathologic phenotypes; however, the molecular determinants underpinning the phenotypic heterogeneity of FTLD-TDP are not well known. It is currently undetermined whether TDP-43 post-translational modifications (PTMs) may be related to the phenotypic diversity of the FTLDs. Thus, the investigation of FTLD-TDP Type A and Type B, associated with GRN and C9orf72 mutations, becomes essential.

Methods: Immunohistochemistry was used to identify and map the intraneuronal inclusions. Sarkosyl-insoluble TDP-43 was extracted from brains of GRN and C9orf72 mutation carriers post-mortem and studied by Western blot analysis, immuno-electron microscopy and mass spectrometry.

Results: Filaments of TDP-43 were present in all FTLD-TDP preparations. PTM profiling identified multiple phosphorylated, N-terminal acetylated or otherwise modified residues, several of which have been identified for the first time as related to sarkosyl-insoluble TDP-43. Several PTMs were specific for either Type A or Type B, while others were identified in both types.

Conclusions: The current results provide evidence that the intraneuronal inclusions in the two genetic diseases contain TDP-43 filaments. The discovery of novel, potentially type-specific TDP-43 PTMs emphasises the need to determine the mechanisms leading to filament formation and PTMs, and the necessity of exploring the validity and occupancy of PTMs in a prognostic/diagnostic setting.

Citing Articles

Prion-like Spreading of Disease in TDP-43 Proteinopathies.

Pongracova E, Buratti E, Romano M Brain Sci. 2024; 14(11).

PMID: 39595895 PMC: 11591745. DOI: 10.3390/brainsci14111132.


Detection of TDP-43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia.

Fontana E, Bongianni M, Benussi A, Bronzato E, Scialo C, Sacchetto L Alzheimers Dement. 2023; 20(2):1156-1165.

PMID: 37908186 PMC: 10917048. DOI: 10.1002/alz.13541.


Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders.

De Marchi F, Munitic I, Vidatic L, Papic E, Racki V, Nimac J Biomedicines. 2023; 11(10).

PMID: 37893165 PMC: 10604382. DOI: 10.3390/biomedicines11102793.


TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP.

Arseni D, Chen R, Murzin A, Peak-Chew S, Garringer H, Newell K Nature. 2023; 620(7975):898-903.

PMID: 37532939 PMC: 10447236. DOI: 10.1038/s41586-023-06405-w.


TDP-43 Proteinopathy Specific Biomarker Development.

Cordts I, Wachinger A, Scialo C, Lingor P, Polymenidou M, Buratti E Cells. 2023; 12(4).

PMID: 36831264 PMC: 9954136. DOI: 10.3390/cells12040597.


References
1.
Li H, Yeh P, Chiu H, Tang C, Tu B . Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One. 2011; 6(8):e23075. PMC: 3151276. DOI: 10.1371/journal.pone.0023075. View

2.
Francois-Moutal L, Perez-Miller S, Scott D, Miranda V, Mollasalehi N, Khanna M . Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Front Mol Neurosci. 2020; 12:301. PMC: 6934062. DOI: 10.3389/fnmol.2019.00301. View

3.
Gruijs da Silva L, Simonetti F, Hutten S, Riemenschneider H, Sternburg E, Pietrek L . Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. EMBO J. 2022; 41(8):e108443. PMC: 9016352. DOI: 10.15252/embj.2021108443. View

4.
Mertins P, Mani D, Ruggles K, Gillette M, Clauser K, Wang P . Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016; 534(7605):55-62. PMC: 5102256. DOI: 10.1038/nature18003. View

5.
Aebersold R, Agar J, Jonathan Amster I, Baker M, Bertozzi C, Boja E . How many human proteoforms are there?. Nat Chem Biol. 2018; 14(3):206-214. PMC: 5837046. DOI: 10.1038/nchembio.2576. View